Do you as a company with a brilliant idea to solve a healthcare issue need to hire a Chief Medical Officer(CMO) at an early stage of your development?
The answer is NO, a perspective
Lets look at a typical job responsibility of a CMO
To perform this job successfully, an individual must be able to perform the following:
InVisionFirst®-Lung demonstrated excellent concordance with tissue profiling and detected 26% more actionable alterations than
standard-of-care testing
Data from two prospective U.S. trials published in Journal Clinical Oncology – Precision Oncology
CAP Accreditation is Awarded to Clinical Laboratories Meeting the Highest Standards in Laboratory Practices
Research Triangle Park, NC and Cambridge, UK, April 18, 2019 -- Inivata, a leader in liquid biopsy, today announces that it has received Accreditation from the College of American Pathologists (CAP) for its CLIA laboratory in Research Triangle Park, North Carolina. The CAP Accreditation is awarded to laboratories which meet stringent quality, accuracy and consistency requirements.
16 April 2019 – Genomics England has announced today the successful completion of the first phase of its collaboration with Inivata and Thermo Fisher Scientific. This is part of a pilot project, undertaken by Genomics England in collaboration with industry, to:
Further Milestone from Janssen on NDA Approval by the US FDA of BALVERSA™ (erdafitinib) for the Treatment of Urothelial Cancer
Businesses across East Anglia are turning to placement students from the University of East Anglia (UEA) to help innovate and grow their organisations.
Increasing numbers of businesses are hosting placement students with many offering them permanent positions when they graduate.
AMSBIO announces XerumFree™ - a new concept in cell culture that allows you to culture cells without the use of serum.
XerumFree™ has been developed taking into account what is missing in traditional basal cell culture media to sustain growth of all cell types, which is a nutritional approach at the cellular level.
Detachin™ Cell Detachment Solution from AMSBIO is a high-performance alternative to Trypsin/EDTA for detaching adherent cells from in vitro growth vessels. Detachin™ provides rapid, gentle, and effective detachment of a wide variety of adherent cells, including primary cells, from all commercially available tissue culture plasticware.
AMSBIO has established a comprehensive portfolio of knock-out cell lines and lysates generated with CRISPR/Cas9 technology.
Using CRISPR/Cas9 gene editing technology for the generation of knock-out cell lines and cell lysates ensures the development of useful tools to validate antibody specificity and elucidate gene function. Knock-out cell lines and cell lysates are widely agreed to be the best negative controls to quickly and confidently prove an antibody’s specificity for a target of interest and ensure reproducibility.